Related Experiment Videos
Protease inhibitor prevents bronchoconstriction in man
European Journal of Respiratory Diseases
|January 1, 1986
Summary
Para-aminomethylbenzoic acid (PAMBA) significantly reduced airway constriction in asthma patients. This protease inhibitor shows potential for managing asthma triggered by analgesics, exercise, or allergens.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Asthma involves complex airways regulation.
- Protease inhibitors are being investigated for their role in managing asthma.
Purpose of the Study:
- To assess the efficacy of para-aminomethylbenzoic acid (PAMBA) as a protease inhibitor in asthma management.
- To evaluate PAMBA's effects on airways regulation in patients with various asthma types.
Main Methods:
- A single-blind study involving 74 asthma patients.
- Oral administration of PAMBA (1.0 g) or lactose placebo.
- Challenge tests included analgesics, exercise, and allergen inhalation, with PEF and FEV1 changes monitored.
Main Results:
- PAMBA significantly reduced maximal changes in FEV1 and PEF across all tested asthma triggers (p ≤ 0.01 for analgesic and exercise-induced asthma; p ≤ 0.05 for allergen-induced asthma).
- The drug demonstrated effectiveness in patients with analgesic-induced (n=30), exercise-induced (n=37), and allergen-induced (n=7) asthma.
Conclusions:
- Para-aminomethylbenzoic acid (PAMBA) effectively mitigates bronchoconstriction in asthma.
- PAMBA may reduce bronchoconstrictory metabolite accumulation by inhibiting phospholipase A2, suggesting a novel therapeutic pathway for asthma.